Kathleen Scott - 20 May 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Chief Financial Officer
Signature
/s/ Kathleen Scott
Issuer symbol
SPRY
Transactions as of
20 May 2025
Transactions value $
-$630,165
Form type
4
Filing time
22 May 2025, 17:00:06 UTC
Previous filing
14 Jan 2025
Next filing
22 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Scott Kathleen D. Chief Financial Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO /s/ Kathleen Scott 22 May 2025 0001794284

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $75,000 +50,000 +6.73% $1.5 57,424 20 May 2025 Direct F1
transaction SPRY Common Stock Sale -$705,165 -50,000 -87.07% $14.1 7,424 20 May 2025 Direct F2
holding SPRY Common Stock 8,250 20 May 2025 By Scott 2008 Trust Dated 3/28/08

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -50,000 -6.23% $0 752,330 20 May 2025 Common Stock 50,000 $1.5 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,475 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
F2 The weighted average sale price for the transaction reported was $14.1033 and the range of prices were between $14.10 and $14.115. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 Immediately exercisable.